News

Under terms of the agreement, iNova will have the exclusive right to market and sell Labopharm’s once-daily tramadol product in Australia. Labopharm will supply iNova with finished packaged

The pivotal trial was designed to evaluate the efficacy and safety of Zuragen for the prevention and treatment of catheter-related bloodstream infection (CRBSI) in end-stage renal disease patients

OmniReliant will use the patented product to compliment the company’s patent pending warming foam acne treatment product. Lead scientists William Bess and Leonard Mackles, who conceived the product,

Data from clinical Phase II and Phase III trials indicate that tapentadol has efficacy comparable to strong, centrally acting analgesics like oxycodone and morphine, whilst offering and at

The study enrolled patients with moderately-to-severely active rheumatoid arthritis (RA) who had an inadequate response to prior treatment with methotrexate (MTX), a disease modifying antirheumatic drug (DMARD). In

The multicenter, open-label, repeat dose clinical trial in chemotherapy induced anemia (CIA) will enroll approximately 100 non-small cell lung cancer, prostate or breast cancer patients who have relapsed

The Phase II study for DSC127, which will be focused on diabetic foot ulcers, is scheduled to begin enrollment in the third quarter of 2008. Derma Sciences obtained

Specifically, in patients with non-mutated KRAS tumors, Vectibix significantly increased progression-free survival (PFS) and had an impact on quality of life (QoL) and disease-related symptoms, compared to best

Cogenics and Epidauros Biotechnologies, both subsidiaries of Clinical Data, will offer the DMET services on a global basis, with limited exclusivity in Europe. The service will enable pharmaceutical